Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06347133 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
A Phase 3 study of Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,456
- Enrollment target
- 20
- Study locations
NCT06347133: Active Phase 3 study of Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.
NCT06347133 is a Phase 3 study of Hypertriglyceridemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 1,456 participants, above the 118-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (1134% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06347133, a Phase 3 study of Hypertriglyceridemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,456 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Plozasiran Injection
Study Locations (20)
California
- Research Site 3 - Beverly Hills
- Research Site 4 - Canoga Park
- Research Site 5 - Garden Grove
- Research Site 6 - Huntington Beach
- Research Site 7 - Lake Forest
- Research Site 8 - Lincoln
- Research Site 9 - Long Beach
- Research Site 10 - Montclair
- Research Site 11 - Oxnard
- Research Site 12 - Redding
- Research Site 13 - Van Nuys
Florida
- Research Site 15 - Clearwater
- Research Site 16 - Hialeah
- Research Site 17 - Lake City
- Research Site 18 - Miami Lakes
- Research Site 19 - Mt. Dora
- Research Site 20 - North Miami Beach
Alabama
- Research Site 1 - Birmingham
- Research Site 2 - Mobile
Colorado
- Research Site 14 - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,456 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT06347133 still lists
NCT06347133 is an interventional study that assigns participants to a tested intervention. Its 1,456 participants enrollment target places it among the larger protocols in the corpus, above the 118-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (1134% higher).
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06347133 names 20 study sites across 4 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06347133 about?
NCT06347133 is a clinical study titled "Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia". This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evalu...
What is the current status of trial NCT06347133?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,456 participants. The study started on 2024-05-21. Estimated completion is 2026-09.
What conditions does trial NCT06347133 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT06347133?
The interventions under investigation include: Placebo (DRUG), Plozasiran Injection (DRUG).
Who is sponsoring clinical trial NCT06347133?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06347133 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06347133's enrollment target sits among peer trials
1,456 1st of 25 higher than 25 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
-
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
COMPLETED · Phase 3
-
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
COMPLETED · Phase 3
-
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
RECRUITING · Phase 2
-
Differential Thrombogenesis by EPA and DHA Mediated by HDL
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI